- Prof Linda Mcgowan talks about research in persistent pelvic pain in general practice to improve the management of those with pelvic pain.
November 2016: The following trial is currently recruiting at several sites in the UK. Please see information about the trial below.
The GaPP2 trial
The GaPP2 trial is testing gabapentin in women with chronic pelvic pain. The GaPP2 researchers want to find out if gabapentin reduces chronic pelvic pain, if there are any side effects of the medicine and how it works.
Gabapentin is a drug that was developed to treat epilepsy, and is currently used to relieve neuropathic pain.
GaPP2 is a randomised, double-blind, placebo-controlled trial:
Randomised: The women who take part will be given either the treatment medicine (gabapentin) or a placebo - a dummy drug that has no active ingredients. A computer makes the selection so it's completely random.
Double-blind The women in the trial won't be told whether they are taking the active medicine (gabapentin) or the placebo - and neither will their doctors. So both are "blinded" to this information.
Placebo-controlled Half of the women in the study will have the active medicine and half the placebo (they are called the control group). The medication that women receive will look exactly the same to them and their doctors, but a completely separate study group will keep a record of which women have gabapentin and which have the placebo.
If you might be interested in taking part in the GaPP2 trial, here's what you need to know
Who can take part
You may be eligible for the GaPP2 trial if you:
Are between 18-50 years
Have chronic pelvic pain of more than 3 months duration
Have had a laparoscopy that could not find the cause of your pain
Are using or willing to use effective contraception if necessary to avoid pregnancy
What the trial involves
We will collect information on pain, and physical and emotional wellbeing at the beginning of the study and after 12 weeks of treatment by questionnaire. Additionally, we will ask a subset of 50 women (recruited in Edinburgh) to have a scan to look at brain activity before and during treatment. We will analyse the brain scan findings to further understand how gabapentin works in women with chronic pelvic pain and possibly also other pain conditions.
The following hospitals are recruiting patients:
Aberdeen Maternity Hospital
Danielle Pirie, Research nurse. Danielle.Pirie@nhs.net 01224 438306
Birmingham Women's Hospital
Virginia Iqbal. Research Nurse. Virginia.Iqbal1@bwnft.nhs.uk 07808200148
Chester: Countess of Chester Hospital
Nichola Kearsley Gynaecology Research Nurse. firstname.lastname@example.org 01244 363379
Glasgow: Queen Elizabeth University Hospital
Therese McSorley, Research nurse. Therese.McSorley@ggc.scot.nhs.uk 0141 232 7600 or 07794692070
Liverpool Women's Hospital
Manchester, St Mary's Hospital
Katie Swindells, Research nurse. Katie.Swindells@cmft.nhs.uk 0161 276 6478
Middlesborough: James Cook University Hospital
Sarah Croft. Research Practitioner.Sarah.email@example.com 01642 835913
Oxford John Radcliffe Women's Hospital
Lisa Buck, Research Midwife Lisa.firstname.lastname@example.org Tel: 01865 221120
Rotherham General Hospital, S Yorkshire
Abby Rand. Research nurse. E-mail Abby.Rand@uhs.nhs.uk 02381 206 856
For more information about the hospitals recruiting and how to get in touch, please visit the trial website
If you have any questions that are not medical or scientific and more about feelings or concerns about the trial, do contact us at email@example.com.